Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integral-2
NCT05905055Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of Nacubactam in complicated urinary tract infection (cUTI), acute pyelonephritis, hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI), sponsored by Meiji Seika Pharma Co., Ltd.. Started Sep 2023; status: completed.
02
Drugs
Nacubactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritishospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT05905055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905055.